Gary L Buchschacher Jr
Overview
Explore the profile of Gary L Buchschacher Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
859
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oh D, He A, Bouattour M, Okusaka T, Qin S, Chen L, et al.
Lancet Gastroenterol Hepatol
. 2024 Jun;
9(8):694-704.
PMID: 38823398
Background: In the preplanned interim analysis of the TOPAZ-1 study, durvalumab plus gemcitabine-cisplatin significantly improved overall survival versus placebo plus gemcitabine-cisplatin in participants with advanced biliary tract cancer. We aimed...
2.
Stearns V, Jegede O, Chang V, Skaar T, Berenberg J, Nand R, et al.
Clin Cancer Res
. 2024 Apr;
30(13):2709-2718.
PMID: 38640040
Purpose: Aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) are common and frequently lead to AI discontinuation. SNPs in candidate genes have been associated with AIMSS and AI discontinuation. E1Z11 is a...
3.
Saad F, Armstrong A, Oya M, Vianna K, Ozguroglu M, Gedye C, et al.
Eur Urol Oncol
. 2024 Apr;
7(6):1394-1402.
PMID: 38582650
Background: The PROpel study (NCT03732820) demonstrated a statistically significant progression-free survival benefit with olaparib plus abiraterone versus placebo plus abiraterone in the first-line metastatic castration-resistant prostate cancer (mCRPC) setting, irrespective...
4.
Pham C, Niu F, Delate T, Buchschacher Jr G, Li Y, Ekinci E, et al.
BioDrugs
. 2023 Sep;
37(6):891-899.
PMID: 37747629
Background: Bevacizumab-awwb was the first biosimilar approved for cancer treatment in the USA. Limited information is available on the real-world comparative safety and effectiveness of bevacizumab biosimilars, especially for indications...
5.
Tomlins S, Khazanov N, Bulen B, Hovelson D, Shreve M, Lamb L, et al.
Commun Med (Lond)
. 2023 Feb;
3(1):14.
PMID: 36750617
Background: Anti-PD-1 and PD-L1 (collectively PD-[L]1) therapies are approved for many advanced solid tumors. Biomarkers beyond PD-L1 immunohistochemistry, microsatellite instability, and tumor mutation burden (TMB) may improve benefit prediction. Methods:...
6.
Powles T, Yuen K, Gillessen S, Kadel 3rd E, Rathkopf D, Matsubara N, et al.
Nat Med
. 2022 Jan;
28(1):144-153.
PMID: 35013615
Early clinical data indicate that some patients with castration-resistant prostate cancer may benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide. The IMbassador250 trial (no. NCT03016312) enrolled 759 men...
7.
Sweeney C, Bracarda S, Sternberg C, Chi K, Olmos D, Sandhu S, et al.
Lancet
. 2021 Jul;
398(10295):131-142.
PMID: 34246347
Background: The PI3K/AKT and androgen-receptor pathways are dysregulated in metastatic castration-resistant prostate cancers (mCRPCs); tumours with functional PTEN-loss status have hyperactivated AKT signalling. Dual pathway inhibition with AKT inhibitor ipatasertib...
8.
Doebele R, Drilon A, Paz-Ares L, Siena S, Shaw A, Farago A, et al.
Lancet Oncol
. 2019 Dec;
21(2):271-282.
PMID: 31838007
Background: Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive solid tumours, including...
9.
Iganej S, Beard B, Chen J, Buchschacher Jr G, Abdalla I, Thompson L, et al.
Oral Oncol
. 2019 Aug;
97:18-22.
PMID: 31421466
Objective: We compared high-dose cisplatin (HDC) vs. triweekly carboplatin (TC)-based chemoradiation in patients with HPV-associated oropharyngeal squamous cell carcinoma (OPSCC). Materials And Methods: A retrospective review was conducted from 2006...
10.
Bhattasali O, Han J, Thompson L, Buchschacher Jr G, Abdalla I, Iganej S
Oral Oncol
. 2018 Mar;
78:151-155.
PMID: 29496043
Objective: The addition of induction chemotherapy (ICT) to concurrent chemoradiation (CCRT) has been investigated as a method of improving outcomes among patients with locally advanced head and neck squamous cell...